Author:
Saposnik Gustavo,Sempere Angel Perez,Raptis Roula,Prefasi Daniel,Selchen Daniel,Maurino Jorge
Funder
Sociedad Española de Neurologia
Roche Farma
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,General Medicine
Reference54 articles.
1. English C, Aloi JJ. New fda-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37:691–715.
2. Bruck W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013;70:1315–24.
3. Sormani MP, Bruzzi P. Can we measure long-term treatment effects in multiple sclerosis? Nat Rev Neurol. 2015;11:176–82.
4. D’Amico E, Leone C, Caserta C, Patti F. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev Neurother. 2015;15:803–24.
5. Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: What works, what does not, and what is needed. Lancet Neurol. 2015;14:194–207.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献